Novo Nordisk is the first biopharmaceutical company to establish an R&D center in China. Beijing R&D Center is an integral part of Novo Nordisk's international R&D plan, which is dedicated to developing new products and new production processes in cooperation with the headquarters. Novo Nordisk has been committed to building Tianjin production plant into an international strategic production base, and has invested a lot of money in the expansion of the plant in order to meet the domestic market while taking into account the export market.
The continued development of Novo Nordisk in China reflects the company's commitment to the China market. We firmly believe that in the near future, China market and R&D work will definitely be in the forefront of the world.
With the increasing incidence of diabetes in China, China has become the second largest country with diabetes patients in the world after Indian.
In order to meet the rapidly growing demand of diabetic patients and professionals in the field of diabetes treatment in China, Novo Nordisk headquarters has implemented a long-term investment strategy in the China market. 1996, the company set up a factory in Tianjin; In May, 2002, the new factory of Novo Nordisk China in Tianjin Economic and Technological Development Zone officially broke ground. In June of the following year, the new factory passed GMP certification and was completed and put into operation in August of the same year.
In September 2005, the factory expansion project was completed, and it was officially put into production in March 2006. After the expansion, the production scale was further expanded and the number of employees exceeded 200. The new factory includes the introduction of a brand-new insulin injection pen -Novo Pen 3 production equipment, which will help meet Novo Nordisk's growing demand for insulin products in Asia and lay a solid foundation for Tianjin production plant to become Novo Nordisk's global strategic production base.
On June 5438+065438+ 10, 2008, Novo Nordisk announced that it would invest in building the world's largest insulin preparation and filling factory in Tianjin, and held a grand groundbreaking ceremony in TEDA Development Zone, Tianjin on&. The new factory will become Novo Nordisk's main production base in the Asia-Pacific region, and provide insulin for China and the global market. Reg injection device and insulin supplement products. The newly-built insulin preparation and filling plant with an investment of nearly US$ 400 million can provide nearly 500 new jobs for China, which is the largest single investment by Novo Nordisk so far and the largest single investment by Novo Nordisk in increasing the production of insulin preparation and filling.